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Abstract 
Hyperprolactinemia is an underappreciated/unknown adverse effects of antipyschotics. 
The consequences of hyperprolactinemia compromise therapeutic adherence and can be 
serious. We present the consensus recommendations made by a group of experts 
regarding the management of antipsychotic-induced hyperprolactinemia. The current 
consensus was developed in 3 phases: 1, review of the scientific literature; 2, 
subsequent round table discussion to attempt to reach a consensus among the experts; 
and 3, review by all of the authors of the final conclusions until reaching a complete 
consensus. We include recommendations on the appropriate time to act after 
hyperprolactinemia detection and discuss the evidence on available options: decreasing 
the dose of the antipsychotic drug, switching antipsychotics, adding aripiprazole, adding 
dopaminergic agonists, and other type of treatment. The consensus also included 
recommendations for some specific populations such as patients with a first psychotic 
episode and the pediatric-youth population, bipolar disorder, personality disorders and 
the elderly population. 
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Highlights 
• Hyperprolactinemia is an underappreciated adverse-effects of antipsychotics 
(APS). 
• Hyperprolactinemia consequences compromise treatment adherence and can be 
serious 
• We recommend routine determination of the prolactin levels of patients 
receiving APS. 
• Treatment strategies include dose reduction, switching APS, or adding an 
antidote.  
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Introduction 
There is growing interest in the physical health of patients with mental disorders (Giner 
et al. 2014; Bobes et al. 2008; De Hert et al. 2010). Given the widespread use of 
antipsychotics (APS) in psychiatric clinical practice, the high frequency of 
hyperprolactinemia in patients receiving these drugs and their potential consequences, 
an important aspect of the physical health of patients under antipsychotic treatment is 
the recognition and management of hyperprolactinemia associated with the use of 
antipsychotics. Hyperprolactinemia is a condition in which a person has a level of 
prolactin above the upper limit of normal range, providing serum sample was obtained 
without excessive venipuncture stress (Melmed et al. 2011); in most laboratories, the 
upper limit for prolactin serum concentrations is set at 20 ng/ml for men and 24–25 
ng/ml for women (Kelly et al. 2013). 
Antipsychotics are usually classified into first-generation or typical antipsychotics 
(Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, 
Pimozide, Prochlorperazine, Thioridazine, Thiothixene, Trifluoperazine) and second-
generation or atypical antipsychotics (Amisulpride, Aripiprazole, Asenapine, Clozapine, 
Iloperidone, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, 
Ziprasidone). The frequency of hyperprolactinemia in patients who receive 
antipsychotics varies among studies but can reach 90% in women and 70% in men 
(Bushe et al. 2008). The frequency of hyperprolactinemia is greater with the first-
generation antipsychotics , amisulpride, risperidone and paliperidone, and is lower with 
aripiprazole and clozapine, with olanzapine and quetiapine occupying a middle ground 
(Holt and Peueler, 2011). Antipsychotic-related hyperprolactinemia is produced by D2 
dopamine receptor blockage, which causes loss of the dopaminergic prolactin inhibitory 
factor in the lactotroph cells in the anterior pituitary. This explains why APS with a 
greater D2 occupation index produce higher and more frequent prolactin elevations 
(Chwieduk and Keating, 2010). This is the case of risperidone (Kinon et al. 2003) and 
its 9-hydroxymetabolite, paliperidone, that cause hyperprolactinemia most often 
(Bellantuono and Santone 2012). Another factor involved is their ability to cross the 
blood-brain barrier: risperidone and paliperidone remain the longest outside of the 
barrier because of their low liposolubility acting for a longer period in the 
tuberoinfundibular pathway, provoking hyperprolactinemia (Besnard et al. 2014). 
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Aripiprazol is a dopamine D2 partial agonist so it rarely provokes hyperprolactinemia 
(Deanna et al. 2013). 
The clinical repercussions of hyperprolactinemia include short-term effects, such as 
amenorrhea, galactorrhea, gynecomastia and sexual dysfunction, and long-term effects, 
such as osteoporosis, prolactinoma, increased cardiovascular risk and the development 
of certain tumors (Bostwick et al. 2009; Cookson et al. 2012). Hyperprolactinemia 
appears within 72 hours after the initiation of antipsychotic treatment (Meltzer et al, 
1976). Serum prolactin levels tend to remain elevated during the length of APS 
treatment (Igarashi et al. 1985). There are important differences between APS and the 
relationship between the concentration of APS in brain and plasma (B/P ratio) using 
PET, which seems to be a biomarker for hyperprolactinemia; the B/P ratio is lower for 
risperidone and sulpiride than for olanzapine and haloperidol. (Arakawa et al.  2010), 
Hyperprolactinemia is more frequent in women in naive patients and does not seem to 
be associated with age or with the severity of the symptoms. (Riecher-Rössler et al. 
2013).A group of experts in psychiatry, internal medicine, endocrinology and oncology 
met to conduct a review of the literature and to form a consensus on the scale of the 
hyperprolactinemia problem secondary to antipsychotic use (i.e., frequency and clinical 
repercussions) and to establish recommendations on its detection and management. The 
results of the analysis of the frequency of the problem and recommendations for its 
detection have been published elsewhere (Montejo et al. 2016). In this work, we present 
the recommendations made by that group with respect to the management of 
hyperprolactinemia associated with the use of antipsychotics.  
Materials and methods 
The current consensus was developed in 3 phases: 1, review of the scientific literature; 
2, subsequent round table discussion to attempt to reach a consensus among the experts 
that took place in Madrid (Spain); and 3, review by all of the authors of the final 
conclusions until reaching a complete consensus. The final result has been agreed upon 
by all of the experts, who reached an agreement by the 4
th
 draft of the manuscript. The 
entire process took place between March 2014 and March 2015.  
1) Review of the scientific literature  
  
7 
 
An extensive review of the scientific literature was conducted to determine the available 
published evidence on hyperprolactinemia associated with APS as well as its causes, 
prevalence and clinical consequences, in addition to issues related to its detection and 
therapeutic strategies. 
A literature search of the PubMed and Cochrane databases was performed using the 
terms “prolactin” and “antipsychotic” or “hyperprolactinemia” in the title and abstract, 
in English language and with no limit on the year of publication. This search provided 
3,341 articles that were narrowed to 267 after filtering for content relevance. This first 
part focused on clinical risks and detection of HPRL in 179 articles. 
2) Consensus roundtable 
A group of 18 experts in Psychiatry (15), Endocrinology (1), Internal Medicine (1) and 
Oncology (1) chosen by the consensus coordinator (ALM) and from different areas of 
Spain and with varying academic, research and clinical fields met in person in Madrid 
in two sessions, morning and afternoon. The consensus was sponsored by the Spanish 
Association of Sexuality and Mental Health (AESexSAME) and the scientific patronage 
of the Spanish Society of Biological Psychiatry. The logistic sponsor did not intervene 
in any of the scientific parts of the consensus or in the preparation of this manuscript. 
Each of the experts was previously responsible for the review of the bibliography 
complied in relation to their area of clinical and research expertise, preparing a 
communication with the most relevant conclusions that were presented successively at 
the in-person roundtable discussion of the consensus conference held in Madrid on 
March 2014. After the in-person discussion session, the review and refinement of the 
conclusions were completed through electronic communications until reaching 
unanimous approval. For the presentation of results, levels of evidence and 
recommendations from the US Agency for Health Research and Quality were taken as a 
reference. Subsequently, a discussion was set based on the evidence presented by each 
speaker to reach a consensus on the evidence and the final content to be reflected in this 
article. The coordinator prepared a preliminary manuscript that was reviewed by all 
members of the consensus, who sent their comments by email. Four consecutive 
reviews of the manuscript were necessary to reach overall consensus during the year 
2014-2015. Conclusions were agreed upon by 100% of the signatories of the consensus. 
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Results 
General Recommendations:  
The general recommendation of the Endocrine Society (Melmed et al. 2011) and 
Spanish Society of Endocrinology (SEEN) (Halperin et al. 2013) for all cases of 
hyperprolactinemia secondary to drugs is that the use of dopaminergic agonists is highly 
controversial given the risk of exacerbating psychotic symptoms and the fact that 
dopaminergic agonists normalize prolactin in only 75% of cases. If the drug responsible 
for hyperprolactinemia cannot be withdrawn, the experts recommend substitutive 
treatment with estrogens/estrogens-progestogens and testosterone in women and men, 
respectively, with symptomatic hypogonadism and/or decreased bone mineral density. 
It is important to determine the appropriate time to act after hyperprolactinemia 
detection. The intensity of elevated serum prolactin and its clinical repercussions in 
each individual case determine the need to act on the prescribed APS treatment; 
additionally, other factors, such as the existence of previous problems of efficacy and/or 
tolerability of other APS, should be considered.  
a) In patients with personal risk factors or a family history of breast cancer and/or 
osteoporosis, the risk of the use of APS associated with hyperprolactinemia 
should be considered (Grade D recommendation). 
b) For a patient with mild and asymptomatic hyperprolactinemia (<50 ng/mL) with 
absence of sexual dysfunction, watchful waiting is recommended, conducting 
regular checks of serum prolactin with at least yearly frequency (Grade D 
recommendation). 
c) In cases of moderate-severe hyperprolactinemia (>50 ng/mL), with clinical 
repercussions and/or prolonged hyperprolactinemia over time, differential 
evaluation and diagnosis from a specialized service is recommended (Grade D 
recommendation). Once assured of the drug-induced origin of the alteration, its 
pharmacological treatment should be considered. It is important to consider the 
limited evidence concerning treatment to date and the difficulty in determining 
with certainty whether findings regarding the treatment of hyperprolactinemia 
are definitively correlated with improvement of the symptoms to which they are 
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attributed, such as sexual dysfunction. Different treatment strategies have been 
described (Montejo and Rico-Villademoros, 2008; Montejo et al. 2010a; 
Montejo et al. 2005; Kelly et al. 2013; Peveler et al. 2008; Carvalo and Góis, 
2011; Nunes et al. 2012) with differing levels of evidence and recommendation 
that include the following: 
1-. Decreasing the dose of the antipsychotic drug 
2.- Switching antipsychotics 
3.- Adding aripiprazole 
4.- Adding dopaminergic agonists 
5.- Another type of treatment 
A summary of the recommendations for managing antipsychotic-induced 
hyperprolactinemia is presented in Figure 1 
[Figure 1 here] 
STRATEGY 1. DECREASING THE DOSE OF THE ANTIPSYCHOTIC 
(LE: IV, grade D recommendation) 
 
This is a priori the simplest strategy but is not without risk of relapse (Haddad and 
Wieck, 2004). Furthermore, the efficacy of this strategy may be questionable, as some 
APS produce hyperprolactinemia even at very low doses; in other APS, the increase in 
prolactin appears to be dose-independent, such as the case of amisulpride (Juruena et al. 
2010). In the Guide of the Endocrinology Society for the Management of 
hyperprolactinemia, a specific recommendation is made to be cautious about 
withdrawing the offending APS drug (Melmed et al. 2011). This strategy may make 
more sense in those cases in which the APS cause of hyperprolactinemia is effective at 
lower doses; the safety of decreasing the dose in each individual case will depend on the 
diagnosis, clinical evolution and pattern of drug treatment. 
STRATEGY 2. CHANGING THE ANTIPSYCHOTIC DRUG 
(LE: Ib-III, Grade A-C recommendation) 
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There are data that support a grade C recommendation for the strategy of switching 
from a high-risk antipsychotic (amisulpride, risperidone, paliperidone or first-generation 
APS) to a lower risk antipsychotic (aripiprazole, quetiapine, olanzapine or ziprasidone). 
It is necessary to determine in such cases whether the patient had been previously 
treated with the alternative drug of choice and whether it was effective in controlling 
psychotic symptoms and/or was well-tolerated by the patient. Available studies provide 
variable tests concerning the risk of relapses and improvement of symptoms related to 
hyperprolactinemia when this strategy is used (Kelly et al. 2013).  However, when 
switching from high doses of antipsychotics, the administration of aripiprazole could 
provoke abrupt psychotic worsening, especially in patients with dopamine 
supersensitive psychosis (Takase et al 2015). The safest strategy is that of gradual and 
overlapping change (Grande et al. 2014) (LE: III). 
Several successful studies have been published concerning changing to aripiprazole 
(LE: III), most of which reported that prolactin levels were reduced significantly 
(Byerly et al. 2009; Lu et al. 2008; Montejo et al. 2010b; Chen et al. 2011; Mir et al. 
2008); 3 studies were undertaken in both sexes (Byerly et al. 2009; Montejo et al. 
2010b; Mir et al. 2008), one in females (Lu et al. 2008) and one in males (Chen et al. 
2011). In only one study was a greater risk of relapses observed (Kuloglu et al. 2010). 
Studies involving changing to olanzapine have reported beneficial effects both in the 
reduction of PRL and the associated clinical symptoms in both sexes (LE: Ib-III) (Kim 
et al. 2002; Kaneda et al. 2004; Kinon et al. 2006; Lin et al. 2006). 
With respect to switching to quetiapine, a randomized double-blind study examined the 
relationship between prolactin levels and sexual dysfunction in 22 men. Both prolactin 
levels and sexual dysfunction were more elevated in the group treated with risperidone 
than in male patients who switched to quetiapine (LE: IIa, Grade B recommendation) 
(Nakonezny et al. 2007). Other studies found improvements in sexual dysfunction in 
both males and females when the sexual dysfunction was controlled by concomitant 
medication, such as serotonergic antidepressants, hormones or beta-blockers (Montejo 
et al. 2005), or no improvement (Byerly et al. 2007). Another series of open studies 
reported normalization of hyperprolactinemia after changing to quetiapine from 
risperidone (LE: III-IV) in male (Byerly et al. 2004) and female patients (Pardal et al. 
2010; Nakajima et al. 2005). 
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In two open studies undertaken in both sexes, the positive effects of switching to 
ziprasidone were studied (LE: IV) (Montejo and Rico-Villademoros, 2008; Weiden et 
al. 2003). Only one study has reported improvement with a switching to clozapine in 
hyperprolactinemia (LE: Ib); however, clozapine should be reserved for those patients 
with treatment-resistant schizophrenia (Breier et al. 1999). 
With respect to more recently approved APS (asenapine, paliperidone, iloperidone, 
etc.), there have been no switching studies in patients with hyperprolactinemia that 
allow the establishment of any type of recommendation in this regard.  
It should be noted that while prolactin levels tend to normalize a few days after stopping 
the causal treatment of hyperprolactinemia, in cases of prolonged exposure, the 
normalization of prolactin levels can be delayed for weeks or even months in the case of 
longer duration APS (Haddad and Wieck, 2004). Prolactin levels tend to normalize 
some days after antipsychotic discontinuation (Montejo 2008). However, with long-
acting injectable APS prolactin levels could remain elevated for several months after 
discontinuation of APS treatment; unfortunately, there is lack of specific information on 
this regard which it is especially important with risperidone and paliperidone. 
STRATEGY 3. ADDITION OF ARIPIPRAZOLE 
(LE: Ia, Grade A recommendation)  
This is the strategy for which a larger and more robust number of studies has been 
published, with several double-blind, randomized controlled trials conducted in both 
sexes (Kane et al. 2009; Shim et al. 2007; Chen et al. 2009), a meta-analysis including 
patients of either sex (Li et al. 2013) and numerous open studies with Depot (Boggs et 
al. 2013; Van Kooten et al. 2011) and conventional drugs that include risperidone 
(Yasui-Furukori et al. 2010; Chen et al. 2010) paliperidone (Roch et al. 2010) and 
others (Ishitobi et al. 2010). 
In a recent meta-analysis of 5 randomized controlled studies with placebo that included 
a total of 639 patients (326 with aripiprazole, 313 in the placebo group) of either sex (Li 
et al. 2013), the addition of aripiprazole at a dose of only 5 mg/day was associated with 
a 79% normalization rate of PRL levels; however, efficacy has been described with 
various doses in female patients (Yasui-Furukori et al. 2010). Positive results were 
published in the case of patients of either sex treated with Depot Risperidone (Ziadi 
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Trives et al. 2013) with aripiprazole dose of 5 mg/day. For some authors, the addition of 
aripiprazole may represent a safer strategy than switching APS for those patients who 
have responded to the causal antipsychotic of HPRL (De Berardis et al. 2014); however, 
there are no comparative studies in this regard. Additionally, it should be noted that 
polypharmacy increase the risk of certain side-effects such as extrapyramidal 
symptoms, diabetes or antispsychotic-induced metabolic syndrome (Citrome et al. 2004; 
Correll et al. 2007; Paton et al 2003). 
STRATEGY 4: ADDITION OF DOPAMINERGIC AGONISTS 
(LE: Ib, Grade B recommendation) 
Most recent publications refer to the use of bromocriptine and cabergoline, although the 
use of amantadine or terguride, a partial dopaminergic agonist, has been described for 
this purpose (Hashimoto et al. 2014). A systematic review conducted in 2011 that 
included patients of either sex concludes that the use of cabergoline is preferable to 
bromocriptine with respect to efficacy and safety (Dos Santos et al. 2011). 
A randomized, controlled study reported efficacy and tolerability with bromocriptine in 
female patients (Lee et al. 2010). Other studies with a lower grade of evidence, 
generally case series with small samples, have also reported efficacy and safety of 
bromocriptine and cabergoline in either sex (García-Rico et al. 2012; Barszcz et al. 
2008; Cavallaro et al. 2004; Tollin, 2000), even in young patients of either sex (mean 
age: 23.3±0.5 years) (Pollice et al. 2007) and male children (Cohen and Biederman, 
2001). 
However, the addition of dopaminergic agonists is a controversial strategy (Peveler et 
al. 2008), as some data suggest that it can aggravate psychosis (Chang et al. 2008), 
increase hallucinations and aggressiveness (Hashimoto et al. 2014) or cause the 
appearance of abnormal involuntary movements (Yvan et al. 2008) and even 
cardiopulmonary complications (Rack et al. 2004; Andersohn et al. 2009). 
According to recommendations by SEEN (Alperin et al. 2013), “this option should only 
be considered, under strict control, in cases in which the antipsychotic drug cannot be 
substituted and there is absolute contraindication of substitutive treatment with 
estrogens/testosterone, or in the special circumstance of women that, within this 
context, desire gestation”. 
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Hence, despite the evidence, this strategy is recommended in cases in which the 
previous strategies have not been possible or effective; more randomized clinical trials 
are needed to determine the efficacy and safety of this method in this group of patients. 
STRATEGY 5. ANOTHER TYPE OF TREATMENT 
In Asian countries, studies have been conducted on the effectiveness of certain types of 
preparations based on medicinal herbs, with good efficacy results and safety, as is the 
case of Peony-Glycyrrhiza Decoction in female patients (Yuan et al. 2008) or 
Shakuyaku-kanzo-to in patients of either sex (Yamada et al. 1997) in the treatment of 
hyperprolactinemia associated with APS use (LE: III, Grade C recommendation). 
If it is not possible to change the treatment, the specific treatment of symptoms 
associated with hyperprolactinemia, such as hypogonadism, sexual dysfunction and 
repercussions on the bone system, may be appropriate. 
 Use of estrogens or testosterone in patients with prolonged hypogonadism and/or 
decreased bone mineral density (Melmed et al. 2011; Halperin et al. 2013). 
 Use of phosphodiesterase inhibitors for the treatment of erectile dysfunction 
associated with HPRL (Gopalakrishnan et al. 2006; Aviv et al. 2004; Mitsonis et 
al 2008). 
 Attempting to curtail risk factors of osteoporosis by promoting a healthy diet and 
regular physical exercise and by avoiding, whenever possible, tobacco and 
alcohol consumption (Grade C recommendation), although in psychotic patients, 
this goal is not easy to achieve.  
 In the case of amenorrhea maintained more than 6 months, if it is not possible to 
change treatment, the use of oral contraceptives is recommended to prevent 
osteoporosis (Peveler et al. 2008). 
 When insufficient levels of vitamin D are detected, supplementation with 800-
1000 IU/day of vitamin D is recommended (Grade B recommendation)  
 In patients with problems following a diet rich in calcium (4-5 daily serving of 
dairy products, equivalent to 1 L of milk), supplementation with 
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pharmacological calcium (500-1000 mg/day) is recommended (Grade B 
recommendation). 
 When the risk of fracture is considered to be very high, pharmacological 
treatment of osteoporosis should be commenced.  
 
Recommendations in some special groups 
FIRST PSYCHOTIC EPISODES AND THE PEDIATRIC-YOUTH POPULATION 
In patients with a first psychotic episode, it is very likely that the initiated APS 
treatment must be maintained for many years with the consequent commitment to 
safety. However, it is well-established that the younger (<18 years of age) population is 
at an increased risk of experiencing adverse effects in the short- (<6 months) and 
medium-term (6-12 months), such as sedation, extrapyramidalism, weight gain, 
dyslipidemia and adverse effects related to prolactin (Correl CU, 2006; Merchán-
Naranjo et al. 2012), with an emphasis on the long-term (>12 months) effects of 
hyperprolactinemia, such as deleterious effects on bone. The latter could impede 
reaching peak bone mass, the maximum of which is reached at approximately 25 years, 
with the resulting future risk of osteoporosis and fracture (Colao et al. 2003; Takahashi 
et al. 2013). 
In a cross-sectional study involving 83 male children or adolescents treated with 
risperidone, a decrease in volumetric bone mineral density in the ultradistal zone of the 
radius and lumbar was observed (Calarge et al. 2010). After adjusting for age, sexual 
maturity, height and body mass index, serum prolactin was found to be inversely 
correlated with bone mass (P< 0.03). Sexual side effects can also intensely affect 
younger patients of either sex, possibly leading to decreased adherence to medication 
(Byerly et al. 2007). 
In a review on the safety data of APS in the pediatric population, a risk profile of 
hyperprolactinemia has been established in the following order, from higher to lower 
risk: paliperidone/risperidone > haloperidol > olanzapine > ziprasidone > quetiapine > 
clozapine > aripiprazole (Ben Amor, 2012). Other systematic reviews of the use of APS 
in the youth population of either sex report an increased risk of hyperprolactinemia with 
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risperidone versus placebo and olanzapine, and with olanzapine vs placebo and a lower 
risk of aripiprazole vs placebo (LE: Ia-II) (Seida et al. 2012; Almandil, 2013) or vs 
active comparatoors (Fraguas et al. 2011). In a review of the pediatric population of 
either sex exposed to APS, frequency of hyperprolactinemia ranged between 50-91% 
for patients treated with risperidone and 90% for haloperidol (Rosenbloom Al, 2010). In 
a cross-sectional study of young male and female patients exposed to APS (Laita et al. 
2007), hyperprolactinemia was detected in 48.5% of patients with more than a year of 
treatment, with a significant correlation observed between prolactin levels and the group 
treated with risperidone (p=0.021). The relevance of this problem in the pediatric-youth 
population has been subject to thorough study, and these results have been recently 
confirmed by a meta-analysis (Druyts et al. 2014) (LE: Ia). 
 
We are waiting for pharmacogenetic strategies that can help us evaluate the long-term 
risks of some of the adverse effects of drugs in carriers of the DRD2*A1 allele (Young 
et al. 2004) and the knowledge of the true gene-environment interaction (Bernardo et al. 
2013). Until then, when treating the pediatric population and first psychotic episodes 
(more common in the youth population), it is especially important to evaluate the 
tolerability profile of the drugs we use; it is advised that the clinic act according to 
consensuses on physical health that relates to patients with severe mental disorders 
(Sainz Ruiz et al. 2008; Bobes et al. 2008; Mané and Bernardo, 2005). 
 
BIPOLAR DISORDER 
Hyperprolactinemia is a common adverse effect in patients of either sex with bipolar 
disorder (BD), given the elevated frequency of APS use, especially in the manic and 
maintenance phases (Vieta et al. 2013a). The new definition of mixed episodes from 
DSM-5 can favor even greater use of antipsychotics (Vieta and Valentí, 2013b; de Dios 
et al. 2014). Unfortunately, there is little published data on the bipolar population, 
although the available evidence suggests that hyperprolactinemia associated with APS 
in BD is lower than in schizophrenia (LE: IIb) (Bushe et al. 2010). The population 
group in which there is more substantiated information is in children and adolescents. In 
a review study of double-blind, placebo-controlled clinical trials that included patients 
of either sex conducted in Spain, it was shown that greater rates of hyperprolactinemia 
occur with risperidone (N=571), with increases from 8.3 to 49.6 ng/ml (Fraguas et al. 
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2011). In other randomized clinical trials conducted in children and adolescents of 
either sex, an average dose of 2.57 mg/day of risperidone was associated with an 
average increase in prolactin from 7.2 to 44.8 ng/ml after 8 weeks of treatment (Geller 
et al. 2012). In another study conducted with olanzapine in adolescents of either sex, 
an11 ng/ml increase in hyperprolactinemia was produced in 47% of patients 
(Kryzhanovskaya et al. 2009). 
 
In bipolar disorder, in addition to APS, another type of drug is usually used, such as a 
mood stabilizer or antidepressant. In the case of mood stabilizers, there are data to 
indicate that valproate does not seem to affect PRL levels in male patients (Aldemir et 
al. 2012) and that lithium may even have a lowering effect on PRL levels both in female 
(El Khoury et al. 2003) and male (Bastürk et al. 2001) patients (LE: IIb). With respect 
to antidepressants, there are more than 40 hyperprolactinemia reports in patients treated 
with selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake 
inhibitors, although there is only one ad hoc study in the case of fluoxetine (which was 
associated with hyperprolactinemia in 12.5% of patients of the study, 4.5% of male 
patients and 22.2% of female patients) (Papakostas, 2006) and sertraline, with negative 
results in female patients (Sagud et al. 2002) (LE: III).  
 
For the hyperprolactinemia approach in bipolar patients, the recommendations of 
screening, follow-up and treatment are largely the same as those generally described for 
hyperprolactinemia from APS. However, with respect to the strategy of changing the 
APS, it is especially important to consider potential interactions of the drug chosen for 
the switching and its polarity index – e.g., its ability to prevent manic versus depressive 
relapses, which can vary considerably from drug to drug (Grade D recommendation) 
(Grande et al. 2014; Bernardo et al. 2011; Popovic et al. 2012).  
 
PERSONALITY DISORDERS 
The use of APS is a phenomenon generalized in the treatment of personality disorders. 
Specifically, the efficacy of APS has been confirmed in more than twenty controlled 
clinical trials with placebo in the treatment of borderline personality disorder (BPD) 
(Vita et al. 2011). 
  
17 
 
Adherence to the treatment of these patients is very low, partly motivated by the poor 
tolerance to the potential adverse effects (Carrasco et al. 2012). Thus, there is 
importance in considering a number of characteristics that could explain increased 
susceptibility to adverse effects associated with HPRL, such as higher prevalence in 
women of childbearing age, patterns of intense and often uncontrolled sexual activity, 
and special intolerance to somatic symptoms, as is apparent in solid epidemiological 
studies in personality disorders (Coid , 2013; Ansell et al. 2007). 
However, the available evidence of hyperprolactinemia repercussions in this population 
group is very low. Only one double-blind study of olanzapine vs placebo in men and 
women with BPD reported a significant increase in prolactin levels and related 
symptoms in 27.5% of the subjects treated with olanzapine compared with 12.1% 
treated with placebo (Schulz et al. 2008). Several case series of patients of either sex 
have also been published in which 40%-70% of patients exhibited abnormally high 
prolactin levels after regular treatment with risperidone (Carrasco et al. 2012). 
 
ELDERLY POPULATION 
The use of APS is common in elderly people (i.e. ≥65 years), particularly in the 
institutionalized population (Alexopoulos et al. 2004). A general characteristic of 
mental diseases in the elderly is the more frequent appearance of psychotic symptoms 
relative to younger adults (for example, in cases of depression, bipolar disorder, 
delirium, schizophrenia or dementia, among others) (Skoog I., 2011). Another common 
risk is their greater sensitivity to some of the adverse effects of APS, such as 
extrapyramidal symptoms, cardiovascular symptoms and those associated with 
hyperprolactinemia (Rado and Janicak, 2012). Older patients tend to accumulate risk 
factors for some of the adverse effects associated with hyperprolactinemia, such as 
sexual dysfunction, osteoporosis and the associated risk of bone fracture, with 
associated consequent functional loss and immobility syndrome (Kinon et al. 2003b; 
Graham et al. 2011). Furthermore, it is likely that in elderly men and women with 
psychotic disorders, adverse effects are present with lower levels of prolactin than in 
younger subjects (Weizman et al. 1983; Bai et al. 2002). In addition, there may be a 
cumulative effect between different causes of hyperprolactinemia, such as the presence 
of hepatic or renal dysfunction and the use of other drugs that increase prolactin (opioid 
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analgesics, some antihypertensives, metoclopramide or domperidone) (Valdés Socin et 
al. 2002; Holt , 2008). 
Hyperprolactinemia detection can be more difficult in older patients, especially in 
women, in whom the post-menopausal stage prevents the use of amenorrhea as a 
sentinel symptom. The effects on sex life are also easily masked, given the decreased 
activity and sexual desire conditioned by other factors (Rubio-Aurioles and Bivalacqua, 
2013). The same can be said about osteoporosis and other clinical consequences. Thus, 
hyperprolactinemia in this population may be particularly harmful.  
 
Conclusions  
Hyperprolactinemia is one of the underappreciated/unknown adverse effects of APS. 
The short-, medium- and long-term consequences of HPRL compromise therapeutic 
adherence and can be serious.  
1. Prolactin is increased after the administration of certain APS; the drugs that 
produce the highest levels of PRL include the typical APS, such as amisulpride, 
paliperidone and risperidone, and those that are less associated with increases 
include clozapine, quetiapine and aripiprazole (which even lowers previous 
prolactin levels).  
 
2. It is necessary to inform patients of the effects associated with 
hyperprolactinemia when it is detected and to decide together the best strategy 
for maintaining efficacy and preserving safety and adherence.  
 
3. Mild hyperprolactinemia levels between 25 and 50 ng/ml should be monitored 
periodically and, in the case of amenorrhea >3 months, a change in APS must be 
assessed for the risk of osteoporosis.  
 
4. Prolactin levels greater than 50 ng/ml and/or associated with clinical 
repercussions (including systematic exploration of possible sexual dysfunction) 
require a treatment intervention, such as decreased dosage, change of APS or the 
addition of drugs with demonstrated ability to reduce prolactin levels 
(aripiprazole).  
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5. Hyperprolactinemia is considered severe when it is > 100 ng/ml (present in 
>30% of patients with risperidone or paliperidone) and must always be 
addressed even when there is no amenorrhea-galactorrhea because of the 
medium/long-term risk of osteoporosis, cardiovascular issues and possible breast 
or endometrial cancer risk increased. Prolactinoma should be ruled out but, 
unfortunately, typically goes unnoticed because of a lack of attention or 
detection by prescribers.  
 
6. When treating a set of often silent and rare side effects reported spontaneously 
by patients, systematic, routine and continuous determination of the prolactin 
levels of patients with APS treatment is recommended.  
 
7. Treatment options for hyperprolactinemia may be considered depending on the 
type of side effect detected, its impact on the patient, and careful weighing of the 
pros and cons of continuing with the current medication or starting a new 
therapeutic strategy.  
 
8. Different treatment strategies have been described with differing levels of 
evidence and recommendation that include the following:  decreasing the dose 
of the antipsychotic drug, switching antipsychotic, adding aripiprazole or adding 
dopaminergic agonists including pros and cons in each one. Selecting a 
personalized strategy for each patient is the best strategy. 
 
9. We need a new intervention model to preserve safety, quality of life and 
adherence to treatment. The model must consider the comprehensive assessment 
of chronic and often silent side effects associated with the use of APS, which are 
often not expressed spontaneously by the patient or underestimated by the 
prescriber but nonetheless compromise quality of life, adherence and safety of 
the patient.   
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Figure 1 
Proposed algorithm for the management of antipsychotic-induced 
hyperprolactinemia 
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Highlights 
 Hyperprolactinemia is an underappreciated adverse-effects of antipsychotics 
(APS). 
 Hyperprolactinemia consequences compromise treatment adherence and can be 
serious 
 We recommend routine determination of the prolactin levels of patients 
receiving APS. 
 Treatment strategies include dose reduction, switching APS, or adding an 
antidote. 
 
 
